# REZILIENT1 (NCT04036682)

> A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: zipalertinib
- Indication: EGFR exon 20 insertion-positive advanced NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04036682
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Cullinan Therapeutics Inc.
- Conditions: Non Small Cell Lung Cancer; EGFR Exon 20 Mutation
- Interventions: CLN-081
- Enrollment: 284
- Primary outcome: All Cohorts: The rate and severity of treatment emergent AEs.
- Primary outcome: All Cohorts: The rate and severity of DLTs.
- Primary outcome: Phase 2 Dose Expansion Cohorts: Overall response rate (ORR)
- Primary outcome: Module A: Pharmacokinetic (PK) parameter
- Primary outcome: Module A: Pharmacokinetic (PK) parameter
- Primary outcome: Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC)

## Indexed commentary on REZILIENT1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 24
- YouTube: 4
- Bluesky threads: 3
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=rezilient1-nct04036682

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04036682", "email": "<work email>"}; the inbox owner confirms by the emailed link.